爱多秀™(ETHOCEL™)药用级乙基纤维素聚合物
爱多秀™产品是获准用于全球制药行业的水不溶性乙基纤维素聚合物,常用于缓释固体剂型配方。
Información General
Tech Bulletin: ETHOCEL™ QbD Case Study
Descargar Documento Enviar por e-mailStudy on the influence of viscosity variation of ETHOCEL (ethylcellulose) on drug release from multiparticulate
dosage forms
Folleto del producto
ETHOCEL™ Product Information Brochure
Descargar Documento Enviar por e-mailETHOCEL Product Information Brochure
Posters publicados
AAPS 2008 - Investigation of Ethylcellulose in the Preparation of Theophylline ER Inert Matrix Tablets
Descargar Documento Enviar por e-mailInfluence of particle size and mol. wt.of ethylcellulose on drug release from inert matrices, with sparingly water soluble drug
AAPS 2014 - A QbD Investigation into the Effect of Ethylcellulose Viscosity Variation on the Drug Release of Metoprolol Tartrate Extended Release Multiparticulates
Descargar Documento Enviar por e-mailStudy showing that viscosity variation, within the manufacturer’s specifications for ETHOCEL Premium grades, has minimal impact on drug release for extended release multiparticulates.
AAPS 2015 - Feasibility of Taste-Masking a Highly Soluble Drug via Powder Layering with Fine Particle Ethylcellulose
Descargar Documento Enviar por e-mailAAPS 2015 Poster Reprint - Demonstrates the feasibility of ETHOCEL FP powder layering, onto drug loaded Suglets, as a highly efficient taste-masking technology.
AAPS 2017 - Stability Evaluation of Ethylcellulose Dry Powder Coated Metoprolol Tartrate Extended Release Multiparticulates
Descargar Documento Enviar por e-mailCRS 2008 - Influence of Solvent Type on ER Coating with Ethylcellulose Barrier Membranes
Descargar Documento Enviar por e-mailInfluence of solvent combinations on EC solution viscosity and drug release from coated beads
CRS 2008 - Investigation of Venlafaxine HCl Release from Extruded and Spheronized Beads Coated with Ethylcellulose using Organic or Aqueous Coating Systems
Descargar Documento Enviar por e-mailOrganic application of EC on venlafaxine HCl extruded and
spheronized beads resulted in a consistent drug release
CRS 2009 - Influence of Coating System Type on Acetaminophen Release from Ethylcellulose Barrier Membrane Coated Multiparticulates
Descargar Documento Enviar por e-mailADS adapted from 2009 CRS poster,The Influence of Coating System Type on Acetaminophen Release from Ethylcellulose Barrier Membrane Coated Multiparticulates
CRS 2010 - Influence of Pore-Former on Drug Release from Ethylcellulose Coated Multiparticulates
Descargar Documento Enviar por e-mailMultiparticulate beads coated with ethylcellulose from an organic solution
CRS 2011 - Influence of Dissolution Media pH on Drug Release from Ethylcellulose Coated Multiparticulates
Descargar Documento Enviar por e-mailComparative evaluation in gastric and intestinal pH media for ionic or non-ionic drugs
CRS 2011 - Influence of Drug Solubility on Release from Ethylcellulose Barrier Membrane Coated Multiparticulates
Descargar Documento Enviar por e-mailSolvent coateding lead to slower drug release than when coated with aqueous dispersion and drug release rate increased with addition of hypromellose as a pore-former
CRS 2014 - Investigation of the Effect of Ethylcellulose Viscosity Variation Using QbD Samples on Drug Release from Extended Release Multiparticulates
Descargar Documento Enviar por e-mailEffect of viscosity variation for ETHOCEL™ QbD samples (Std. 10, 20 and 100 Premium grades) coated onto drug layered multiparticlates.
RS 2009 - Influence of Molecular Weight on Drug Release from Ethylcellulose Barrier Membrane Multiparticulates
Descargar Documento Enviar por e-mailDrug release is retarded with increasing molecular weight (viscosity) of EC
主要的药物应用:
- 多微粒缓释包衣
- 活性成分的微囊
- 药物的苦味遮盖剂
- 惰性骨架系统中的缓释粘合剂
- 溶剂和挤压制粒
爱多秀™乙基纤维素为制药应用提供了灵活的配方:
- 不同的分子量范围,可以组成中等粘度的混合物
- 具有超细粉末(FP)规格,可用于惰性缓释骨架系统,并且可通过增大表面积而改善亲脂性
- 与水溶性辅料(例如美多秀™优质纤维素醚类)配合使用时,能调节释放性能
制药行业已经广泛应用爱多秀™达50年以上。本品具有优异的安全记录,得到了全球制药行业的认可,并且符合《美国食用化学品集》的要求,在欧洲和美国还被许可用作食品添加剂。
爱多秀™/美多秀™/ETHOCEL™ / METHOCEL™ IFF公司注册商标。 © 2021 IFF.版权所有
Plataforma de soluciones
Colorcon puede ayudarlo a reducir el tiempo en su proyecto al proporcionar la solución adecuada a través de la selección de excipientes y guía del proceso.
Productividad
Bajar el costo total y reducir el tiempo de lanzamiento al mercado
Diseño de disolución
Gestión del ciclo de vida de producto mediante un portfolio para perfiles de liberación modificada y extendida.
Cumplimiento del paciente
Reducir los errores en la medicación y mejorar la adhesión del paciente al tratamiento
Estabilidad
Performance del producto final estable y consistente
Autenticación de producto
Seguimiento y localización